Bristol-Myers Squibb

AI Score

XX

Unlock

60.65
0.23 (0.38%)
At close: Mar 21, 2025, 2:55 PM
0.38%
Bid 60.57
Market Cap 123.07B
Revenue (ttm) 48.31B
Net Income (ttm) -8.95B
EPS (ttm) -4.41
PE Ratio (ttm) -13.75
Forward PE 8.46
Analyst Hold
Ask 60.75
Volume 6,545,236
Avg. Volume (20D) 10,978,818
Open 60.23
Previous Close 60.42
Day's Range 59.84 - 61.34
52-Week Range 39.35 - 63.33
Beta 0.44

About BMY

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for th...

Sector Healthcare
IPO Date Jun 1, 1972
Employees 34,100
Stock Exchange NYSE
Ticker Symbol BMY
Full Company Profile

Analyst Forecast

According to 14 analyst ratings, the average rating for BMY stock is "Hold." The 12-month stock price forecast is $61, which is an increase of 0.59% from the latest price.

Stock Forecasts

Next Earnings Release

Bristol-Myers Squibb is scheduled to release its earnings on Apr 24, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+3.67%
Bristol-Myers Squibb shares are trading higher aft... Unlock content with Pro Subscription
1 month ago
-2.32%
Bristol-Myers Squibb shares are trading lower. The company announced Phase 2 TRANSCEND FL trial evaluating Breyanzi in adult patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma.